文献速递结核与非结核分枝杆菌

药物遗传学对HIRIF试验中一线抗结核药物药代动力学的影响

Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF Trial.
PubMed 文献 · J Infect Dis · 2025-01-01

本研究为HIRIF试验的药物遗传学子研究,纳入90名有药代动力学数据的秘鲁参与者,对NAT2、SLCO1B1、AADAC和AOX1位点的单核苷酸多态性进行基因分型。结果显示,NAT2标签SNP rs1495741与常规6-SNP面板预测的表型一致率为91%,且能更好地预测异烟肼AUC;SLCO1B1 rs4149032等位基因频率为0.31,似乎影响20 mg/kg剂量下利福平的AUC和Cmax。

要点

  • NAT2标签SNP rs1495741与6-SNP面板预测表型一致率91%,对异烟肼AUC预测更优。
  • SLCO1B1 rs4149032等位基因频率0.31,似乎影响20 mg/kg利福平的AUC和Cmax。
  • AADAC rs1803155与利福平PK无关,AOX1 rs55754655与吡嗪酰胺PK无关联。

核心结论

  • 标签SNP方法可能为异烟肼药代动力学提供更简单和廉价的预测。
  • SLCO1B1 SNP对利福平药代动力学的影响需在本次及其他人群中进一步探索。

研究设计与样本

  • HIRIF试验的药物遗传学子研究,纳入90名有药代动力学数据的秘鲁参与者。
  • 使用实时PCR对NAT2、SLCO1B1、AADAC和AOX1位点的相关单核苷酸多态性进行基因分型。

主要发现

  • 常规6-SNP NAT2面板预测的慢、中、快乙酰化者比例分别为32.5%、48.2%和19.2%。
  • NAT2标签SNP rs1495741与面板预测表型一致率为91%,且是异烟肼AUC更好的预测因子。
  • 考虑面板未代表的罕见等位基因或通过观察AUC可明确解决的差异后,标签SNP的敏感性为97.7%。
  • SLCO1B1 rs4149032等位基因频率为0.31,在20 mg/kg剂量下似乎影响利福平AUC和Cmax。
  • AADAC rs1803155在研究人群中占主导,与利福平PK无关,但可能因样本量和等位基因频率而遗漏效应。

关键数值与推荐

  • 常规6-SNP NAT2面板预测的慢乙酰化者比例为32.5%。
  • 常规6-SNP NAT2面板预测的中乙酰化者比例为48.2%。
  • 常规6-SNP NAT2面板预测的快乙酰化者比例为19.2%。
  • NAT2标签SNP rs1495741与面板预测表型一致率为91%。
  • 考虑差异后标签SNP的敏感性为97.7%。

临床怎么用

  • 标签SNP方法可能提供更简单和廉价的异烟肼药代动力学预测。
  • SLCO1B1 SNP对利福平药代动力学的影响需进一步探索。

局限性

  • AADAC SNP与利福平PK的效应可能因样本量和等位基因频率而被遗漏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Variability in the pharmacokinetics (PK) of first-line antituberculosis drugs (rifampicin [RIF], isoniazid [INH], and pyrazinamide [PZA]) is high and may be influenced by pharmacogenetic polymorphism. We performed a pharmacogenetic substudy in 90 participants with PK data from the HIRIF trial in Peru. METHODS: Relevant single-nucleotide polymorphisms (SNPs) in the NAT2, SLCO1B1, AADAC, and AOX1 loci were genotyped using real-time polymerase chain reaction (PCR). RESULTS: The proportions of slow, intermediate, and fast acetylators predicted by a conventional 6-SNP NAT2 panel were 32.5%, 48.2%, and 19.2%, respectively. A single NAT2 tag SNP (rs1495741) agreed with the panel-predicted phenotype in 91% and was a better predictor of INH area under the curve (AUC). Accounting for discrepancies possibly caused by rare alleles not represented in the panel or that could be unequivocally resolved using observed AUC, sensitivity of the tag SNP was 97.7%. A previously described SNP in SLCO1B1 (rs4149032) was present at an allele frequency of 0.31 and appeared to influence RIF AUC and maximum concentration (Cmax) at a dose of 20 mg/kg, despite an extreme distribution of alleles across the randomized arms. The AADAC SNP (rs1803155) predominated in the study population and was not linked to RIF PK, although an effect could have been missed due to sample size and allele frequency. There was no association between PZA PK and a common SNP in AOX1 (rs55754655). CONCLUSIONS: A tag SNP approach may offer simpler and cheaper prediction of INH PK. Further exploration of the impact of SLCO1B1 SNPs on RIF PK is required in this and other populations. Clinical Trials Registration. NCT01408914.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mackay E, Platt G, Peloquin CA, et al. Impact of Pharmacogenetics on Pharmacokinetics of First-Line Antituberculosis Drugs in the HIRIF Trial. J Infect Dis. 2025. PMID: 40239986. doi:10.1093/infdis/jiaf195

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。